Perioperative Immunotherapy for NSCLC (ECTOP-1030)

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

200

Participants

Timeline

Start Date

September 1, 2024

Primary Completion Date

September 1, 2026

Study Completion Date

September 1, 2029

Conditions

Lung Cancer

Interventions

DRUG

Atezolizumab

atezolizumab adjuvant therapy

DRUG

Nivolumab

nivolumab neoadjuvant therapy

DRUG

Pembrolizumab

pembrolizumab neoadjuvant+adjuvant therapy

All Listed Sponsors

lead

Fudan University

OTHER

NCT06572722 - Perioperative Immunotherapy for NSCLC (ECTOP-1030) | Biotech Hunter | Biotech Hunter